{
  "archetypes": {
    "merger_arb": {
      "name": "Merger Arbitrage",
      "base_rates": {
        "friendly_definitive": 0.94,
        "strategic_buyer_bonus": "+2-3%",
        "hostile": 0.38
      },
      "adjustments": {
        "third_party_veto": -1,
        "doj_ftc_lawsuit": -2,
        "spread_below_2.5": "KILL"
      },
      "position": {
        "max_size": 0.03,
        "kelly": 0.25,
        "skew": "negative"
      },
      "entry_timing": "Immediate after announcement",
      "kill_screens": ["hostile_deal", "merger_spread"]
    },
    
    "pdufa": {
      "name": "PDUFA / FDA Binary",
      "base_rates": {
        "post_nda": 0.92,
        "with_adcom_positive": 0.97,
        "crl_resub_manufacturing": [0.60, 0.70],
        "crl_resub_efficacy": [0.30, 0.40]
      },
      "therapeutic_area_loa": {
        "hematology": 0.26,
        "rare_disease": 0.25,
        "infectious_disease": 0.19,
        "cns_neurology": 0.08,
        "oncology_all": 0.05,
        "solid_tumor": 0.04
      },
      "position": {
        "max_size": 0.015,
        "kelly": 0.25,
        "skew": "negative",
        "note": "Reduced from 2% in v3.6 due to 2.7x rejection/approval asymmetry"
      },
      "entry_timing": "Pre-catalyst",
      "red_flags": [
        "Single-arm studies without comparator",
        "Trend toward significance language",
        "Emphasis on secondary endpoints",
        "Per protocol analysis (not ITT)",
        "First novel mechanism",
        "Missed primary endpoint"
      ]
    },
    
    "activist": {
      "name": "Activist Campaigns",
      "base_rates": {
        "post_upc_overall": 0.53,
        "tier_1": 0.83,
        "tier_2": 0.80,
        "tier_3": 0.40,
        "settlement_rate": 0.92
      },
      "tier_definitions": {
        "tier_1": ["Elliott", "Starboard", "ValueAct", "Pershing Square"],
        "tier_2": ["Trian", "Icahn", "Third Point"],
        "tier_3": ["First-time activists", "Small funds"]
      },
      "tier_bonus": {
        "tier_1": 1.0,
        "tier_2": 0.5,
        "tier_3": 0
      },
      "sourcing": {
        "frequency": "daily",
        "primary_sources": [
          "SEC EDGAR 13D filings (sec.gov/cgi-bin/browse-edgar)",
          "13D Monitor (13dmonitor.com)",
          "Activist Insight (activistinsight.com)"
        ],
        "tracking_criteria": {
          "tier_1": "Track ALL filings immediately (Elliott, Starboard, ValueAct, Pershing Square)",
          "tier_2": "Track if stake >7.5% or board demands (Trian, Icahn, Third Point)",
          "tier_3": "Track only if turnaround/sale process announced"
        },
        "event_triggers": [
          "Initial 13D filing with stake >5%",
          "13D amendment with board demands",
          "Standstill expiration dates",
          "Proxy contest announcements"
        ],
        "target_pipeline": "Maintain 8-12 active activist events (balanced with other archetypes)"
      },
      "position": {
        "max_size": 0.06,
        "kelly": 0.25,
        "skew": "negative"
      },
      "entry_timing": "On 13D filing",
      "avg_settlement_days": 16.5
    },
    
    "spinoff": {
      "name": "Spin-offs",
      "base_rates": {
        "year_1": "Underperformance common",
        "year_2": "Peak outperformance",
        "parent_prep_6mo_plus": "+50% first-year returns"
      },
      "entry_timing": {
        "optimal_window_days": [30, 60],
        "rationale": "Forced index selling creates -2.4% to -3.7% underperformance in first 5 days",
        "exception": "Immediate S&P 500 inclusion",
        "volume_signal": {
          "pattern": "Volume decline to <1.5x 20-day average + price stabilization",
          "rationale": "Signals forced selling exhaustion vs. continued distribution"
        }
      },
      "position": {
        "max_size": 0.08,
        "kelly": 0.50,
        "skew": "positive"
      }
    },
    
    "liquidation": {
      "name": "Liquidations",
      "base_rates": {
        "spac_at_discount": 0.99,
        "cef": 0.95,
        "orderly_corporate": [0.80, 0.95],
        "biotech": 0.35
      },
      "position": {
        "max_size": 0.10,
        "kelly": 0.50,
        "skew": "positive"
      },
      "entry_timing": "At discount to NAV/trust",
      "kill_screens": ["altman_z_score"]
    },
    
    "insider": {
      "name": "Insider Clusters",
      "base_rates": {
        "cluster_3_plus_2_weeks": [0.65, 0.70],
        "distressed_context": 0.70,
        "conviction_no_distress": 0.55
      },
      "position": {
        "max_size": 0.05,
        "kelly": 0.25,
        "skew": "negative"
      },
      "entry_timing": {
        "base_signal": "On cluster detection",
        "volume_overlay": {
          "threshold": "2x 20-day average",
          "rationale": "Insiders buy during quiet periods. Volume surge signals market discovery",
          "max_wait_days": 90,
          "note": "Not a scored filter. Used only for timing execution on scored ideas â‰¥8.25"
        }
      },
      "kill_screens": ["beneish_m_score"]
    },
    
    "legislative": {
      "name": "Legislative Catalysts",
      "base_rates": {
        "primary_beneficiaries": "Low (often priced in)",
        "secondary_beneficiaries": "Higher (overlooked)",
        "state_ballot": "Binary (threshold risk)"
      },
      "beneficiary_penalty": {
        "primary_obvious": -1.5,
        "secondary_overlooked": 0,
        "macro_sensitive": -1.0
      },
      "position": {
        "max_size": 0.02,
        "kelly": 0.25,
        "skew": "negative"
      },
      "entry_timing": "3-6 months pre-passage",
      "kill_screens": ["macro_conflict"],
      "red_flags": [
        "Obvious beneficiary status",
        "Rate sensitivity conflicts",
        "Commodity exposure conflicts",
        "2-4 year implementation timeline"
      ]
    }
  }
}
